Nrx Pharmaceuticals Stock Price To Earnings To Growth
| NRXP Stock | USD 1.20 0.01 0.84% |
NRX Pharmaceuticals fundamentals help investors to digest information that contributes to NRX Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of NRX Stock. The fundamental analysis module provides a way to measure NRX Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NRX Pharmaceuticals stock.
NRX | Price To Earnings To Growth |
NRX Pharmaceuticals Company Price To Earnings To Growth Analysis
NRX Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
NRX Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for NRX Pharmaceuticals is extremely important. It helps to project a fair market value of NRX Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since NRX Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NRX Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NRX Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
NRX Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, NRX Pharmaceuticals has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
| All Next | Launch Module |
NRX Fundamentals
| Return On Equity | -6.83 | ||||
| Return On Asset | -1.16 | ||||
| Current Valuation | 19.54 M | ||||
| Shares Outstanding | 12.09 M | ||||
| Shares Owned By Insiders | 23.56 % | ||||
| Shares Owned By Institutions | 6.00 % | ||||
| Number Of Shares Shorted | 565.8 K | ||||
| Price To Book | 2.90 X | ||||
| EBITDA | (30.02 M) | ||||
| Net Income | (30.15 M) | ||||
| Cash And Equivalents | 24.55 M | ||||
| Cash Per Share | 0.36 X | ||||
| Total Debt | 9.16 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.58 X | ||||
| Book Value Per Share | (1.42) X | ||||
| Cash Flow From Operations | (21.66 M) | ||||
| Short Ratio | 4.80 X | ||||
| Earnings Per Share | (2.11) X | ||||
| Target Price | 31.67 | ||||
| Beta | 1.27 | ||||
| Market Capitalization | 14.51 M | ||||
| Total Asset | 7.32 M | ||||
| Retained Earnings | (253.15 M) | ||||
| Working Capital | (12.16 M) | ||||
| Net Asset | 7.32 M |
About NRX Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NRX Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NRX Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NRX Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with NRX Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NRX Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NRX Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with NRX Stock
Moving against NRX Stock
| 0.75 | BMY | Bristol Myers Squibb | PairCorr |
| 0.73 | GILD | Gilead Sciences | PairCorr |
| 0.62 | ESPR | Esperion Therapeutics | PairCorr |
| 0.4 | DNA | Ginkgo Bioworks Holdings | PairCorr |
| 0.35 | FLGC | Flora Growth Corp | PairCorr |
The ability to find closely correlated positions to NRX Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NRX Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NRX Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NRX Pharmaceuticals to buy it.
The correlation of NRX Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NRX Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NRX Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NRX Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.